cc 4

High affinity and subtype selective α6β2 and α4β2 partial agonist (Ki values are 12 and 26nM for rat α6β2 and α4β2 receptors respectively). Has low affinity for α3β4 and α7 receptors (Ki values are 4.8 and 13 μM for human α3β4 and rat α7 receptors respectively). Stimulates dopamine release from striatal slices in vitro. Attenuates nicotine-induced self-administration and conditional place preference in rats. Sala et al (2013) CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking c Br.J.Pharmacol. 168 835 PMID:22957729 |Riganti et al (2005) Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells. Br.J.Pharmacol. 146 1096 PMID:16273122 |Carbonnelle et al (2003) Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes. Eur.J.Pharmacol. 471 85 PMID:12818695

High affinity JNK inhibitor (Ki values are 25-50 nM). Inhibits JNK via competitive binding of the ATP-binding site of active, phosphorylated JNK. Exhibits > 40-fold selectivity for JNK over p38, ERK, IKK2, protein kinase C, Lck and ZAP70. Hepatoprotective. Also inhibits HCMV replication. Uehara et al (2004) c-Jun N-terminal kinase mediates hepatic injury after rat liver transplantation. Transplantation. 78 324 PMID:15316358 |Uehara et al (2005) JNK mediates hepatic ischemia reperfusion injury. J.Hepatol. 42 850 PMID:15885356 |Ma et al (2007) A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J.Am.Soc.Nephrol. 18 472 PMID:17202416 |Ma et al (2009) Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab.Invest. 89 470 PMID:19188913 |Zhang et al (2015) The c-Jun N-terminal kinase inhibitor SP600125 inhibits human cytomegalovirus replication. J.Med.Virol. 87 2135 PMID:26058558 |Vasilevskaya et al (2015) Inhibition of JNK sensitizes hypoxic colon cancer cells to DNA-damaging agents. Clin.Cancer.Res. 21 4143 PMID:26023085

ARCC 4 negative control is a negative control for ARCC 4. Binds androgen receptors (AR) without inducing degradation.

STF31 是一种葡萄糖转运蛋白 1 的选择性抑制剂，IC50为 1 μM。

Pomalidomide (CC-4047) 是一种抗血管生成剂和免疫调节剂。Pomalidomide 是泛素 E3 连接酶 cereblon (CRBN) 的配体，常用于 PROTAC 产品的合成。

Tamarixetin (4'-O-Methyl Quercetin) 是一种槲皮素的天然类黄酮衍生物，具有抗氧化、抗炎作用，能够防止心肌肥厚。

ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide and it is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 effectively degrades clinically relevant AR mutants associated with antiandrogen therapy[1].

(S,R,S)-AHPC-C4-NH2 hydrochloride (E3 ligase Ligand-Linker Conjugates 28) 是一种合成的 E3 连接酶配体- linker 偶联物，包含基于 (S,R,S)-AHPC 的 VHL 配体和 linker。

(S,R,S)-AHPC-C4-NH2 dihydrochloride is a chemically derived E3 ligase ligand-linker conjugate, consisting of the (S,R,S)-AHPC VHL ligand and a linker specifically designed for EED-Targeted PROTAC[1].

(S,R,S)-AHPC-C4-NH2 is a custom-synthesized conjugate of an E3 ligase ligand-linker, which combines the VHL ligand based on (S,R,S)-AHPC and a linker specifically designed for EED-Targeted PROTAC[1].

CC-401 is a specific inhibitor of JNK (Ki: 25-50nM).

THCCC, a PHCCC analog, is a dual metabotropic glutamate receptor 2 3 negative positive allosteric modulator.

CC-401 Hydrochloride (CC401 HCl) 是 JNK 抑制剂(Ki= 25~50 nM)。

STF-62247 是一种自噬诱导剂，在 RCC4 和 RCC4 VHL 细胞中的IC50分别为 0.625 μM 和 16 μM。它对 VHL 缺陷型肾细胞癌有选择性的细胞毒性。

Metitepine is a serotonin receptor antagonist in the CNS used as an antipsychotic.

CD4 (81-92) is a peptide that was previously found to inhibit gp120 binding, HIV-1 infectivity, and syncytium formation.

GCC-4401C methanesulfonate is a factor Xa inhibitor similar to rivaroxaban that is currently under development for venous thromboembolic disease (VTE).

JNJ-39729209 is a TRPV1 antagonist.

GCC-4401C free base is a factor Xa inhibitor similar to rivaroxaban that is currently under development for venous thromboembolic disease (VTE).

Minretumomab (CC-49) 是针对 TAG-72（tumor-associated glycoprotein 72）的鼠源单克隆抗体，适用于癌症和免疫研究领域。

C 021 dihydrochloride 是一种 CC 趋化因子受体 4 (CCR4) 拮抗剂，抑制人和小鼠的功能趋化性，IC50分别为 140 和 39 nM。C-021 (4-​Quinazolinamine, 2-​[1,​4'-​bipiperidin]​-​1'-​yl-​N-​cycloheptyl-​6,​7-​dimethoxy-) 可有效阻止人 CCL22 衍生的 [35S]GTPγS 与受体结合，IC50为 18 nM。

Dovramilast (CC-11050) 是一种具有口服活性的磷酸二酯酶4(PDE4)抑制剂，，可以减少促炎介质和细胞因子的产生。Dovramilast 可用于研究结核分枝杆菌感染和红斑狼疮。

Apremilast (CC-10004) 是一种口服有效的磷酸二酯酶 4 抑制剂，IC50为 74 nM。它抑制脂多糖释放TNF-α，IC50为 104 nM。

Apremilast D5 (CC-10004 D5) is a deuterium-labeled Apremilast. Apremilast is an orally available inhibitor of PDE-4 (IC50: 74 nM). Apremilast inhibits TNF-α release by lipopolysaccharide (IC50: 104 nM).